AM-095

• CAT Number: I000895
• CAS Number: 1228690-36-5
• Molecular Formula: C₂₇H₂₄N₂O₅
• Molecular Weight: 456.49
• Purity: ≥95%
• Target: LPA Receptor
• Solubility: DMSO: ≤ 67.3 mg/mL
• Storage: Store at -20°C
• IC50: 0.98/0.73 uM (human/mouse LPA1)
• InChI: InChI=1S/C27H24N2O5/c1-17-25(28-27(32)33-18(2)20-6-4-3-5-7-20)26(34-29-17)23-14-12-22(13-15-23)21-10-8-19(9-11-21)16-24(30)31/h3-15,18H,16H2,1-2H3,(H,28,32)(H,30,31)/t18-/m1/s1
• InChIKey: LNDDRUPAICPXIN-GOSISDBHSA-N
• SMILES: CC1=NOC(=C1NC(=O)OC(C)C2=CC=CC=C2)C3=CC=C(C=C3)C4=CC=C(C=C4)CC(=O)O

AM-095(CAT: I000895) represents a significant advancement in the field of G protein-coupled receptor (GPCR) modulation and drug discovery. As a potent antagonist of the lysophosphatidic acid receptor 1 (LPA1), AM-095 demonstrates its effectiveness by inhibiting LPA1 receptor activity. With IC50 values of 0.98 μM for recombinant human LPA1 and 0.73 μM for mouse LPA1, this compound exhibits a strong affinity for the LPA1 receptor. Its ability to selectively target LPA1 receptors makes AM-095 a valuable tool for investigating the physiological roles of LPA signaling and exploring potential therapeutic interventions.

Reference

[1]. AM095, a lysophosphatidic acid (LPA) receptor 1 antagonist, in various in vitro and in vivo models of fibrotic disease.
[2]. Castelino, Flavia V.; Seiders, Jon; Bain, Gretchen et al. Amelioration of dermal fibrosis by genetic deletion or pharmacologic antagonism of lysophosphatidic acid receptor 1 in a mouse model of scleroderma. Arthritis & Rheumatism (2011), 63(5), 1405-1415.
[3]. Swaney, J. S.; Chapman, C.; Correa, L. D. et al. Pharmacokinetic and pharmacodynamic characterization of an oral lysophosphatidic acid type 1 receptor-selective antagonist. Journal of Pharmacology and Experimental Therapeutics (2011), 336(3), 693-700.